Table 2.
MAMMARY TUMORS | |||
cfa-let-7f | ↑ | hsa-let-7f-5p | ↑ |
cfa-miR-15a | ↓ | hsa-miR-15a-5p | ↓ |
cfa-miR-16 | ↓ | hsa-miR-16-5p | ↓ |
cfa-miR-17-5p | ↓ | hsa-miR-17-5p | ↓ |
cfa-miR-21 | ↑ | hsa-miR-21-5p | ↑ |
cfa-miR-29b | ↑ | hsa-miR-29b-3p | ↑ |
cfa-miR-125b | ↓ | hsa-miR-125b-5p | ↓ |
cfa-miR-145 | = | hsa-miR-145-5p | ↓ |
cfa-miR-155 | ↓ | hsa-miR-155-5p | ↓ |
cfa-miR-181b | ↑ | hsa-miR-181b-5p | ↑ |
EMT | |||
cfa-miR-141 | ↓ | hsa-miR-141-3p | ↓ |
cfa-miR-200a | ↓ | hsa-miR-200a-5p | ↓ |
cfa-miR-200b | ↓ | hsa-miR-200b-5p | ↓ |
cfa-miR-200c | ↓ | hsa-miR-200c-5p | ↓ |
cfa-miR-429 | ↓ | hsa-miR-429 | ↓ |
B-CLL/T-CLL | |||
cfa-miR-15a | ↓/↓ | hsa-miR-15a-5p | ↓/– |
cfa-miR-16 | ↓/↓ | hsa-miR-16-5p | ↓/– |
cfa-miR-21 | ↑/↑ | hsa-miR-21-5p | ↑/– |
cfa-miR-29b | ↑/↑ | hsa-miR-29b | ↓/– |
cfa-miR-125b | ↑/↓ | hsa-miR-125b | ↑/– |
cfa-miR-150 | ↑/↑ | hsa-miR-150-5p | ↑/– |
cfa-miR-155 | ↑/↑ | hsa-miR-155-5p | ↑/– |
cfa-miR-181a | ↓/↓ | hsa-miR-181a-5p | ↓/– |
MELANOMA | |||
cfa-miR-145 | ↓ | hsa-miR-145-5p | ↓ |
cfa-miR-203 | ↓ | hsa-miR-203a | ↓ |
cfa-miR-205 | ↓ | hsa-miR-205-5p | ↓ |
OSTEOSARCOMA | |||
cfa-miR-134 | ↓ | hsa-miR-134 | ↓ |
cfa-miR-544 | ↓ | hsa-miR-544a | ↓ |
In the 1st column are the canine and in the 3rd the human miRNAs listed. In the 2nd and 4th column the relative expression or tendencies in comparison to non-neoplastic samples are presented. “–” indicates that no reports were found for involvement in CLL. “=” means that no differences in expression between tumor and healthy cells were described. “↑” signifies upregulation or “↓” downregulation in comparison to non-neoplastic samples.